Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (NASDAQ: AZTA) generates news through quarterly earnings releases that detail performance across its Sample Repository Solutions and Genomic Services businesses. These reports reveal how pharmaceutical industry R&D spending patterns affect demand for automated storage systems and contract laboratory work. Investors track revenue breakdowns by segment and geography to understand which parts of the life sciences tools market drive growth.
The company announces partnerships with pharmaceutical firms, biotechnology companies, and research institutions that adopt Azenta's cold-chain storage infrastructure or contract sequencing services. Product launches introducing new automated storage capabilities or expanded genomic analysis offerings signal technology investments. Regulatory approvals for clinical sample storage facilities in new countries indicate geographic expansion supporting multinational drug development programs.
Strategic developments including acquisitions of complementary laboratory service providers or sample management technology companies shape Azenta's competitive position within the life sciences tools sector. Share repurchase authorizations and capital allocation decisions reflect management's financial strategy. Industry analysts cover Azenta as a proxy for pharmaceutical innovation activity, since drug development programs require the sample storage and genomic services the company provides.
This page aggregates real-time news coverage of Azenta's business developments, competitive positioning, and market dynamics affecting the life sciences tools industry. Bookmark this resource to monitor how shifts in pharmaceutical R&D investment and biotechnology funding impact Azenta's two operating segments.
Azenta, Inc. (Nasdaq: AZTA) has rescheduled its second fiscal quarter earnings release for 2022 from May 3, 2022, to May 9, 2022, due to delays in the quarter-end closing process following the sale of its Semiconductor Automation business on February 1, 2022. The company anticipates that the second quarter revenue and non-GAAP EPS will remain within the previously issued guidance range. A conference call is scheduled for May 9, 2022, at 4:30 p.m. ET to discuss the financial results.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 second quarter earnings on May 3, 2022, after market close. The results will cover the quarter ending March 31, 2022. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day, accessible via phone and live webcast. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services to major pharmaceutical and biotech companies worldwide.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, featuring a presentation at 9:30 am ET. The event will be accessible via a live webcast on the Azenta investor relations website, with a replay available afterward. Azenta provides comprehensive life sciences solutions, focusing on cold-chain sample management and genomic services for pharmaceutical and biotech industries globally. The company rebranded from Brooks Automation to Azenta, Inc. on December 1 last year.
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22, 2022. The event will feature a presentation at 3:00 PM ET in a virtual format, accessible via Azenta's investor relations website.
Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services for drug development and clinical research. The company rebranded from Brooks Automation, Inc. on December 1.
Azenta, Inc. (Nasdaq: AZTA) will participate in the Barclays Global Healthcare Conference on March 15, 2022, with a presentation at 10:15am ET. The event takes place in Miami, FL, and a live webcast is available on Azenta's investor relations website. A replay will also be accessible post-event. Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services. The company rebranded from Brooks Automation on December 1, adopting the new name and ticker symbol.
Azenta, Inc. (Nasdaq: AZTA) will participate in Cowen's 42nd Annual Health Care Conference on March 8, 2022, with a live presentation at 2:10 PM ET. The conference will be held virtually, and interested parties can access the live webcast via the Azenta investor relations website. A replay will be available after the event. Azenta is a global leader in life sciences solutions, providing cold-chain sample management and genomic services to the pharmaceutical and biotech industries.
Azenta, Inc. (Nasdaq: AZTA) reported Q1 fiscal 2022 results with revenue of $140 million, an 18% increase year-over-year. Life Sciences Services grew 24%, while Life Sciences Products saw a 10% rise. Diluted EPS from continuing operations was $0.04, with total diluted EPS at $0.58. The company completed the divestiture of its semiconductor automation business for $3 billion, expected to net about $2.4 billion. Guidance for Q2 2022 anticipates revenue between $137 million and $147 million, with non-GAAP earnings per share between $0.07 and $0.15.
Azenta, Inc. (Nasdaq: AZTA) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, presenting at 10:30 a.m. EST. The company, a leader in life sciences solutions, recently rebranded from Brooks Automation, enhancing their focus on critical areas like drug development and clinical research.
Headquartered in Chelmsford, MA, Azenta aims to expedite breakthroughs in healthcare through reliable cold-chain sample management and genomic services. For details, visit www.azenta.com.
Azenta, Inc. (Nasdaq: AZTA) announced the successful completion of the sale of its Semiconductor Solutions Group to Thomas H. Lee Partners for $3.0 billion in cash, with net proceeds expected to be about $2.4 billion. The company allocated approximately $50 million of the sale proceeds to pay off its term loan, while terminating its revolving line of credit. Following this transaction, Azenta will concentrate exclusively on the life sciences industry, planning to utilize the net proceeds for strategic investments.
Azenta, Inc. (Nasdaq: AZTA) will announce its fiscal 2022 Q1 earnings on February 8, 2022, after market close. A conference call to discuss the results will be held the same day at 4:30 p.m. ET. Investors can access the live webcast on Azenta's website, with a replay available on February 9 at 8:30 a.m. ET. The company, a leader in life sciences solutions, has rebranded from Brooks Automation, Inc. and is in the process of selling its Semiconductor Solutions Group business, which is classified as discontinued operations for reporting purposes.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
